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Abstract 
 
Purpose of review: Intestinal helminth infections continue to cause significant morbidity in 
resource limited settings. Recent efforts at global control have centered on Mass Drug 
Administration (MDA) of praziquantel and benzimidazole anthelminthics to reduce the 
prevalence and intensity of schistosomiasis and soil transmitted nematode infections, 
respectively. This review summarizes progress and potential challenges associated with MDA. 
Recent findings: Data from studies conducted in endemic areas show that chemotherapeutic 
interventions can reduce prevalence and intensity of infection with intestinal helminths, and 
have the potential to reduce transmission within populations. However, consistent benefits in 
high risk groups, including children and pregnant women, have not been established. The long 
term benefits of MDA remain to be determined, and the potential for emerging resistance to 
impact effectiveness have not yet been defined. 
Conclusions: While studies evaluating MDA have shown benefit in certain populations, 
intensive monitoring and evaluation, as well as a commitment of resources for new drug 
development are essential for long-term control or elimination of intestinal helminth infections. 
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Introduction 
Targeted and/or community based Mass Drug Administration (MDA) of anthelminthic 
chemotherapy presently serves as a cornerstone of global efforts to reduce morbidity and 
mortality caused by parasitic worms. The rationale for MDA as a means of control is based on 
evidence from trials demonstrating individual benefit attributable to reduced intensity of 
infection, as well as its potential to limit transmission through overall reductions in prevalence 
and intensity within communities at risk. While MDA has the potential to alleviate disease 
burden in endemic communities, there are potential hazards in relying so heavily on currently 
available chemotherapeutic agents for global helminthiasis control. In addition to significant 
disparities in effectiveness at the community-level, expanded distribution of drugs with limited 
efficacy will likely hasten the emergence of resistant strains and increase exposure to potential 
toxicity, which necessitates commitment of additional expenditures to ensure essential 
monitoring of safety and impact. This review will highlight critical achievements and ongoing 
uncertainties surrounding the implementation of MDA for the control of soil transmitted 
nematode (STN) infections and schistosomiasis. 
 
Global epidemiology and burden of parasitic helminths  
As many as 4 billion people live in countries endemic for one or more of the major STNs, 
specifically Ascaris lumbricoides, Trichuris trichiura, and hookworms (Ancylostoma duodenale, 
A. ceylanicum, and Necator americanus) [1, 2]. It is estimated that one out of every two people 
living in a developing country is infected with at least one STN [3], and the cumulative burden of 
disease, as measured in Disability Adjusted Life Years (DALYs), approximates the impact of 
major global killers like malaria and tuberculosis [4, 5]. 
 
With as many as 740 million people infected worldwide, hookworm is one of the most 
common parasitic infections associated with the rural poverty [6-9]. The highest prevalence and 
intensity of infection occurs in Sub-Saharan Africa (29%), followed by China (16%), South (16%) 
and East (26%) Asia, and the Americas (10%) [10, 11]. Hookworms infect nearly 200 million 
people in sub-Saharan Africa, and are responsible for up to 34% of the total disease burden 
[12]. These parasites are typically acquired through skin contact with soil contaminated with 
larvae, although Ancylostoma are also infectious when ingested orally. Adult worms attach to 
the small intestine, where they feed on blood and tissue using sharp teeth or cutting plates. The 
major clinical sequelae of hookworm infection include anemia, malnutrition, and growth delay, 
although light infections are usually asymptomatic. 
 
Infections with the roundworm Ascaris lumbricoides (26.6 million DALYs) and whipworm 
Trichuris trichiura (10.5 million DALYs) are also widespread, affecting more than a billion people 
in the tropics [4-6]. After ingestion of fertilized eggs through fecal oral contact, A. lumbricoides 
larvae migrate through the lungs before reaching the adult stage in the small intestine. Although  
light infections are often asymptomatic, high intensity ascariasis is frequently associated with 
intestinal obstruction due to the size of adult worms, as well as malabsorption and growth delay 
[4, 5, 13]. In contrast to A. lumbricoides, T. trichura eggs develop during transit in the gut, with 
adult worms residing in the large intestine. Infection with T. trichiura causes anemia, 
malnutrition, and cognitive deficits, as well as an uncommon but severe form of colitis (Trichuris 
dysentery). School-aged children living in areas of extreme poverty are at highest risk for 
infection with Ascaris and Trichuris and the corresponding clinical consequences [3, 4, 13, 14]. 
Along with the age-associated peaks in prevalence and intensity of infection, children are often 
co-infected with all three STNs [4, 11], which can lead to synergistic negative effects on 
nutritional status, growth, and ultimately productivity [13]. 
 
Schistosomiasis is endemic in 74 countries [15*] and affects between 190 – 250 million 
people, at least 85% of whom live in sub–Saharan Africa [15*-18]. The economic and social 
burden of the disease is often underestimated [19] due to the lack of accurate data [20]. 
Schistosomiasis is associated with two distinct disease manifestations (intestinal and 
urogenital), which are caused by different parasite species. Intestinal schistosomiasis is caused 
mainly by Schistosoma mansoni and S. japonicum, with S. intercalatum, S. mekongi and S. 
malayensis found in limited geographical areas[18]. Urogenital schistosomiasis is caused by S. 
haematobium, which has been referred to as the “neglected schistosome” despite its significant 
global impact [21]. In Africa alone, annual S. haematobium associated mortality is estimated at 
150,000, compared to 130,000 for S. mansoni [22]. 
 
The complex schistosome life cycle includes a developmental stage within an 
intermediate snail host. Humans acquire the infection through contact with freshwater 
contaminated with the infectious cercarial stage, and following tissue migration, adult 
schistosomes reside within the veins of the intestine (S. mansoni, S. japonicum) or bladder (S. 
hematobium). Adult female worms release eggs, which lodge in the liver or bladder and elicit a 
profound host inflammatory response. Disease is attributable primarily to chronic inflammation, 
which results in liver cirrhosis, cystitis, bladder cancer, and in women, genital lesions that 
promote susceptibility to sexually transmitted infections, including HIV [21].  
 
Evidence for a positive impact of Mass Drug Administration 
 The use of MDA has been proposed as an effective means of reducing morbidity from 
schistosomiasis and STNs by decreasing the intensity of infection and limiting transmission 
within endemic communities [23-25]. Anthelminthics remain integral in control programs against 
soil-transmitted helminths due to their low cost and widespread availability [13, 26, 27]. The 
range of single-dose oral anthelminthics recommended by the World Health Organization 
(WHO) for treatment of STN infections include the benzimidazoles albendazole (400 mg) and 
mebendazole (500 mg), as well as levamisole (2.5 mg/kg), and pyrantel pamoate (10 mg/kg) 
[13], while praziquantel (40 mg/kg) is currently recommended for treatment of schistosomiasis. 
Most STN control programs exclusively use benzimidazoles due to the availability of single-dose 
regimens, safety, and ease of administration in children [28]. Albendazole has become the 
preferred agent for many MDA programs targeting STNs due to a unique broad spectrum of 
activity, including efficacy against immature larval stages, and low toxicity in the host, and 
reduced effectiveness of mebendazole with repeated use [29, 30]. The efficacy of mebendazole 
varies considerably due to factors such as preexisting diarrhea and gastrointestinal transit time, 
intensity of infection, and strain diversity in helminth parasites [31, 32]. 
 
The recent WHO report on soil transmitted helminthiasis [15*] and a series of reviews 
[27, 33-39] provide excellent overviews of the last twenty years of global control efforts. The 
2001 World Health Assembly Resolution WHA54.19 [40] recommended annual deworming in 
areas with >20% prevalence of STNs and schistosomiasis, and bi-annual treatment if 
prevalence is >50%, with an initial goal of achieving regular administration of chemotherapy for 
at least 75% of at-risk school age children (SAC) by 2010. Rapid scale up has led to reported 
coverage of over 170 million pre-SAC, and over 220 million SAC in 2010 [41]. Many endemic 
countries have adopted a strategy of a school based MDA supplemented by a community 
component to effectively reach children who are not in school [42, 43].  
 
In a recent study conducted in Uganda, large-scale MDA of praziquantel achieved 
substantial reductions in S. mansoni reinfection and community transmission [44]. Subsequent 
modeling analyses demonstrated that MDA also reduced the rate of parasite acquisition over 
the four year study period, providing evidence of an effect on transmission as well as disease. In 
2009, the National Neglected Tropical Diseases control program in Sierra Leone conducted a 
school-based MDA program using praziquantel and mebendazole. Targeting school-age 
children in schistosomiasis endemic areas with a single-round treatment regimen, the overall 
prevalence and intensity of S. mansoni and hookworm infections post-MDA was significantly 
reduced compared to pre-MDA levels (69.0% to 38.2% for schistosomiasis and 41.7% to 14.5% 
for hookworm, respectively) [45]. Interruption of schistosomiasis transmission has been 
achieved in selected endemic regions, including Puerto Rico, Iran and Japan through a 
combination of disease control efforts and broader socioeconomic growth [15*, 35**]. Together, 
these promising results have enabled the Schistosomiasis Control Initiative (SCI) and other 
national control programs to galvanize efforts to expand access to praziquantel via MDA 
initiatives [46]. 
 
With regard to STNS, surveys in areas of targeted chemotherapy in school children 
suggest an overall decrease in intensity and prevalence of Ascaris, Trichuris, and hookworm 
over time, even though elimination has not been achieved [47-50]. Improvements in morbidity 
have also been reported [20], with countries such as Uganda [51], Sierra Leone [45], and Kenya 
[52] reporting significant reductions in prevalence and intensity of both schistosomiasis and 
hookworm following implementation of MDA. Hookworm prevalence has decreased in Asia and 
the Americas over the past few decades, likely through a combination of economic development 
and institution of control programs [6]. For example, the prevalence of hookworm in Thailand 
decreased from 40.6% in 1982 to 11.4% in 2001 [53],while the overall prevalence of STNs in 
China also dropped significantly between 1990 (53.6%) and 2003 (19.6%) [5]. A recent report 
from Zanzibar, after four years of annual MDA with albendazole and praziquantel, demonstrated 
reductions in the prevalence of Trichuris and hookworm, although a slight increase in Ascaris 
was observed [54]. In all, there is evidence that MDA has the potential to reduce morbidity 
through reductions in prevalence and intensity of infection with STNs in highly endemic areas, 
and recent commitments from the donor community should allow for sustained access to low 
cost benzimidazoles. 
 
Shortcomings and potential risks of MDA 
While encouraging reports suggest that in certain communities MDA can reduce 
prevalence and intensity of infection with geohelminths, measurable benefits of deworming have 
not been observed in all settings [55*]. For example, early schistosomiasis control programs that 
utilized praziquantel did not lead to substantive reductions in the prevalence and intensity of 
infection [56, 57]. Recent reviews have found limited effects of deworming on anemia in 
pregnant women or on birth outcomes [58*, 59]. A Cochrane review of 34 randomized trials and 
a subsequent meta-analysis also identified no or only modest differences in weight gain, while 
no significant effect of deworming was shown for cognitive function or school performance in 
children compared to placebo [60**, 61]. Part of the explanation may be the heterogeneity in 
distribution of parasite species across (and within) communities, coupled with the fact that 
benzimidazoles are not uniformly active against all three STNs [7, 62]. While both mebendazole 
and albendazole remain highly effective for the treatment of ascariasis, their activity against 
hookworm is quite variable, and neither drug works particularly well against Trichuris. Therefore, 
currently available drugs may lack the broad clinical efficacy necessary to control STN infections 
on a worldwide scale. 
 
Our recent field research illustrates another cautionary example, namely the risk of 
extrapolating data from selective communities to the broader population. In Ghana, the 
prevalence of STN infections ranges from approximately 40% in the central part of the country, 
to as high as 87% in the rural north [63, 64]. In 2007, a cross-sectional study of 292 children and 
adults in the Kintampo North Municipality in central Ghana [65] revealed a 44.9% overall 
prevalence of hookworm infection (in the absence of other STNs), with 93% of infected 
individuals having light infections (<2000 eggs per gram feces). Directly observed treatment with 
single dose albendazole (400mg) resulted in a cure rate of 61% and a fecal egg count reduction 
(FECR) rate of 82%, which is below the 90% FECR rate threshold proposed for effective 
therapy [62]. A second study in 2010 enrolled children ages 6-11 years old (n=286) from 16 
schools in Kintampo North, and confirmed a comparable prevalence (39%) of low intensity 
hookworm infection. Albendazole treatment was again associated with a low cure rate (44%), 
and also with a sub-optimal FECR rate of 87%. In our most recent field study, we enrolled 
children ages 6-13 (n=141) in 5 contiguous Kintampo communities, with a specific goal of 
probing factors associated with treatment response. We observed an overall albendazole cure 
rate of 40%, but surprisingly found that treatment responses varied widely based on village of 
residence. For example, while albendazole therapy was associated with cure rates of greater 
than 70% and 95% FECR rates in one village, in the contiguous community treatment had no 
measurable effect (0% cure rate; 0% FECR rate). This striking and unexpected difference in 
response across closely situated villages with comparable prevalence and intensity profiles 
implies that the projected benefit of MDA to individual communities might also be expected to 
vary widely. Moreover, in communities like those in Kintampo, which are characterized by 
moderate prevalence (approximately 40%) of low intensity (<2,000 epg) hookworm infection, it 
may not be justified on public health or ethical grounds to subject children to repeated MDA in 
the absence of evidence demonstrating effectiveness and most importantly, clinical benefit at 
the local level. These data establish the need, if not obligation, to commit necessary resources 
for thorough monitoring and evaluation of deworming programs, as has been suggested [34, 
66]. Furthermore, the wide variation in response to deworming across parasite species and 
geographic regions raises doubts about the potential to achieve global control of STN infections 
by scaling up distribution of currently available anthelminthics. 
 
In addition to unproven public health benefits of MDA, recent reports also highlight 
potentially negative effects of deworming, specifically an increase in the risk of allergies and 
autoimmune disorders [59, 67]. For example, a randomized trial in Uganda found that 
albendazole treatment during pregnancy increased the risk of eczema among infants, while 
praziquantel during pregnancy also increased the risk of eczema, but only in infants of mothers 
with schistosomiasis [59]. Individuals with Multiple Sclerosis who were infected with STNs 
exhibited fewer relapses than those without worms, and that deworming was associated with 
significant exacerbations of symptoms [67]. These studies lend credence to theories ascribing 
potentially beneficial roles that low intensity helminth infections might play in modulating host 
immunity. 
 
Lastly, widespread implementation of mass chemotherapy will eventually result in the 
development of resistance to currently available anthelminthics, including the benzimidazoles 
and praziquantel. Although there has been no indication or evidence of resistance of the 
parasite to praziquantel, cases of individual failures have been reported, and in vitro studies 
demonstrate the capacity of schistosomes to develop tolerance to praziquantel [68]. With regard 
to hookworm, there have been reports of reduced efficacy of pyrantel, mebendazole, and 
albendazole [25, 28, 69-71]. In fact, two recent trials in Vietnam found that only a three dose 
regimen of albendazole was more effective than placebo against hookworm, while single dose 
albendazole and a three dose regimen of mebendazole were not [72]. Our data from Ghana 
(see above) confirm that the response to albendazole is quite variable across local 
communities, which creates an opportunity, if not a responsibility, to monitor for evidence of 
emerging resistance. The experience gleaned from programs to control veterinary nematodes 
clearly demonstrates that it is simply a matter of time before resistance will emerge in 
populations repeatedly exposed to broad spectrum anthelminthics. These concerns underscore 
the need for intensive monitoring of control programs for evidence of reduced effectiveness in 
endemic populations. 
 
Conclusion  
It is too soon to know the potential impact of MDA, especially if adopted at a national or 
global scale, with regard to long term health effects or the emergence of parasite resistance 
[27**]. Given the recent donor-driven push to scale up MDA, it is imperative that adequate 
resources be allocated for intensive monitoring and active surveillance to identify changes in 
disease epidemiology, potential toxicities, and emerging anthelminthic resistance, despite 
limited Ministry of Health budgets in most endemic areas [27**, 38*, 73]. Changes in prevalence 
of infections following MDA also necessitate regular revisions to cost-benefit analyses to stay 
abreast of changing conditions. Some have already recommended altering the thresholds for 
treatment, and instituting three-tiers of treatment to more effectively and cost-effectively deliver 
anthelminthics [3]. Simultaneous investments in new drug development will be critical to 
sustaining any progress made once parasite resistance emerges [36]. Ultimately, new strategies 
designed to augment treatment efficacy, decrease susceptibility to infection through improved 
nutritional status, as well as development of new drugs and/or vaccines could significantly 
improve the likelihood of achieving global control, if not elimination, of intestinal helminth 
infections.  
 
 
Key points: 
 
• Mass Drug Administration (MDA) using anthelminthic drugs is being widely implemented 
to control soil transmitted nematodes and schistosomiasis in endemic populations.  
• Evidence suggests that MDA has the potential to reduce morbidity from chronic helminth 
infections and may also block transmission, although the benefits of currently available 
deworming therapies are not uniform across communities and risk groups. 
• The long term impact of expanded MDA is unknown, and could result in emerging 
parasite resistance and unexpected health consequences, thereby altering existing cost-
benefit analyses. 
• Monitoring and evaluation of MDA, especially at the local community level, is necessary 
to ensure that treatments are safe, effective, and achieve the desired public health 
benefit. 
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